Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
APL)]] (1) ·
Dual orexin receptor antagonist (DORA) (1) ·
[[:Category:5-alpha-reductase_inhibitors|5α-reductase inhibitor]] (1) ·
[[:Category:Androgen_modulators|Androgen modulator]] (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (1) ·
[[:Category:Antineoplastics|Antineoplastic (oral (1) ·
[[:Category:Beta-3_agonists|β3 adrenergic agonist]] (1) ·
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (1) ·
[[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (1) ·
[[:Category:Incretin_modulators|Incretin pathway modulator]] (1) ·
[[:Category:Overactive_bladder_medications|Overactive bladder medication]] (1) ·
[[:Category:Retinoids|Retinoid]] (1) ·
[[:Category:Topical_retinoids|Topical retinoid]] (1)
mechanism:
uses:
Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) ·
'"`UNIQ--vote-0000052E-QINU`"', '"`UNIQ--vote-0000052F-QINU`"', '"`UNIQ--vote-00000530-QINU`"' (1) ·
'"`UNIQ--vote-00000BA0-QINU`"', '"`UNIQ--vote-00000BA1-QINU`"', '"`UNIQ--vote-00000BA2-QINU`"' (1) ·
'"`UNIQ--vote-00000C4C-QINU`"', '"`UNIQ--vote-00000C4D-QINU`"' (1) ·
'"`UNIQ--vote-0000117B-QINU`"' (1)
starting dose:
25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) ·
25 mg PO once daily; titrate to 50 mg after 4-8 weeks if needed (1) ·
5 mg PO daily for BPH; 1 mg PO daily for androgenetic alopecia (1) ·
5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) ·
Topical: pea-sized amount to dry face at bedtime, building from 2-3×/week to nightly as tolerated; oral APL: 45 mg/m²/d in divided doses (1)
preparations:
fda max: (Click arrow to add another value)
routes:
onset:
BPH symptom improvement at 3-6 months; prostate volume reduction over 6-12 months; hair regrowth at 6-12 months (1) ·
Postprandial glucose effect within days; HbA1c by 12 weeks (1) ·
Symptom improvement within weeks (1) ·
Topical: irritation within days; acne improvement 6-12 weeks; oral APL response within days (1) ·
~30 min (1)
duration:
halflife:
~0.5-2 hours (oral)'"`UNIQ--ref-00000BA3-QINU`"' (1) ·
~12 hours (effective); terminal much longer'"`UNIQ--ref-0000117C-QINU`"' (1) ·
~5-6 hours in young men, ~8 hours in elderly'"`UNIQ--ref-00000531-QINU`"' (1) ·
~50 hours'"`UNIQ--ref-00000C4E-QINU`"' (1) ·
~8 hours (shorter than suvorexant and lemborexant) (1)
bioavailability:
25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"' (1) ·
Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing'"`UNIQ--ref-00000BA4-QINU`"' (1) ·
~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' (1) ·
~62% (1) ·
~63% (oral)'"`UNIQ--ref-00000532-QINU`"' (1)
pregnancy:
None (1) ·
'''Pregnant individuals should not handle crushed/broken tablets''' (skin absorption risk); can cause hypospadias in male fetus. Not used in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; avoid (1) ·
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 5 results in range #1 to #5.